Parikh Anand Kiran 4

What Happened

• Anand Parikh, President, CEO and Director of Sensei Biotherapeutics (FTH), recorded a conversion of derivative securities on 2026-06-15. The filing shows disposal of 761.428 shares of Series B Preferred (derivative) and acquisition of 761,428 shares of common stock. No cash price is reported (N/A).
• Conversion math: each Series B Preferred share converts into 1,000 common shares per the Certificate of Designation, so 761.428 Series B Preferred → 761,428 common shares. This reflects a conversion related to the Merger described in the filing, not an open-market buy or sale.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-16 (timely).
• Transaction code: C (conversion of derivative security).
• Price: N/A — no cash paid/received in the conversion.
• Shares recorded: Disposal of 761.428 Series B Preferred (derivative); Acquisition of 761,428 common shares.
• Shares owned after transaction: not specified in the filing.
• Notable footnotes:
  • F1: Each Series B Preferred is convertible into 1,000 common shares and has no expiration.
  • F2/F3: Conversion follows the February 17, 2026 Merger Agreement that resulted in HoldCo common being exchanged for 761.428 Series B Preferred shares.
• Filing timeliness: filed the day after the transaction (appears timely under Form 4 rules).

Context

• This was a conversion of a derivative (preferred) into common stock — a corporate capitalization event tied to the Merger — not a market purchase or sale. Such conversions are routine and do not by themselves indicate insider buying or selling sentiment.
• The filing shows both the disposal of the derivative interest and the acquisition of common shares to reflect the change in holdings after conversion.